LNSR earnings analysis
What we found in LNSR's 10-Q: the parts that mattered, the offsets in the same document, and what the company said about what comes next.
Our reading of the filing · Free to read, no account needed
LENSAR delivered a materially improved quarter, with revenue of $16.495 million versus approximately $14 million in 2025 Q2 and diluted EPS of $0.10 versus a $0.15 loss. Recurring revenue, procedure revenue and procedure volume grew 20%, 23% and 13%, respectively, while the company added a $10.0 million revolving facility and held $13.6 million of cash and investments. However, near-term profitability remains uncertain, with management expecting continued losses, an accumulated deficit of $137.7 million, tariff-related margin pressure and increased competitive and regulatory risks.
The parts that mattered.
Pulled out of the filing itself, with the figures the company reported.
- Revenue grew and beat consensus
- Revenue was $16.495 million, up from approximately $14 million in 2025 Q2 and above the $14.65 million consensus estimate by $1.845 million.
- EPS turned positive
- Diluted EPS was $0.10 versus a $0.15 loss in 2025 Q2 and the $0.27 loss consensus, marking a return to quarterly profitability.
- Recurring and procedure trends improved
- Recurring revenue, procedure revenue and procedure volume increased 20%, 23% and 13%, respectively, versus the prior-year quarter.
- Liquidity supported by cash and unused revolver
- The company held $13.6 million of cash, cash equivalents and short-term and long-term investments at June 30, 2026, and had no borrowings under its revolving credit facility as of August 13, 2026.
- New $10 million revolving facility
- On August 10, 2026, the company entered into a $10.0 million asset-based revolving credit facility, expanding potential liquidity capacity through August 10, 2028.
- No reported control deficiencies
- Management concluded that disclosure controls were effective at the reasonable-assurance level as of June 30, 2026, and reported no material changes in internal control during the quarter.
And the other side of it.
The offsets in the same document — the things a summary that only listed the good news would have left out.
- Profitability and liquidity remain uncertain
- Liquidity remains dependent on execution: cash, cash equivalents and investments totaled $13.6 million at June 30, 2026, while the company states it expects to continue incurring near-term losses and had an accumulated deficit of $137.7 million.
- Credit facility imposes constraints
- The new $10.0 million revolving facility requires at least $3.0 million of cash to remain on deposit until specified EBITDA conditions are met and includes a 1.25-to-1.00 debt-service-coverage requirement beginning as early as March 31, 2027 or the first quarter in which the facility is drawn.
- Customer and distributor concentration
- The company relies on international distributors, and one customer represented approximately 14% of revenue for the six months ended June 30, 2026, creating concentration and distributor-dependency risk.
- Tariffs pressure margins
- Tariffs have increased component costs for the ALLY System and PIDs; management states it has not passed those costs to customers, negatively affecting gross margin, and that tariff refunds may not fully offset related costs.
- New competitor product expected
- Bausch + Lomb anticipates launching its second-generation SeeLyra femtosecond laser in the second half of 2026, creating a potential competitive threat to the ALLY System.
- Medical-device compliance burden increased
- The FDA Quality Management System Regulation became effective February 2, 2026, and may impose additional or different compliance requirements despite the company’s ISO 13485-oriented quality system.
What they reported.
What the company itself reported, taken out of the document.
- Earnings per share
- $0.1
- Segment
- Recurring revenue: increased 20% versus the prior-year quarter; dollar amount not disclosed.
- Segment
- Procedure revenue: increased 23% versus the prior-year quarter; dollar amount not disclosed.
- Segment
- Procedure volume: increased 13% versus the prior-year quarter; dollar amount not disclosed.
What they said about what is next.
No quantitative revenue or EPS guidance was provided in the supplied 10-Q text. Management stated that current cash and cash equivalents, together with future product-sale and lease cash generation, are expected to fund operations for at least one year from the financial-statement issuance date.
The filing reads better than the one before it.
What came before.
- 10-Q · May 8, 2026
- LENSAR, Inc. reported poor performance for Q4 2026, with revenue of $16.025 million and an EPS of -0.12, failing to meet expectations. The company saw a revenue decline of 5% compared to the prior year, primarily due to…
- 10-K · April 30, 2026
- LENSAR, Inc. delivered a mixed performance in its latest 10-K filing for the fiscal year ended December 31, 2025. The company reported total revenues of $68 million for the year, showing growth from prior periods…
- 10-K · March 31, 2026
- LENSAR positions itself as a commercial-stage medical device company focused on advanced laser systems (LLS and ALLY) to address corneal astigmatism and improve refractive cataract outcomes. Revenue was roughly flat…
- 10-Q · May 8, 2025
- Revenue rose to $14.159M in Q1 2025 from $10.588M in Q1 2024 (+$3.571M, +33.7%), driven mainly by Product sales; however, operating loss widened to $(5.790)M and GAAP net loss jumped to $(27.345)M due to a $21.714M…
This is our reading of a public filing, not the filing. Read the original on SEC.gov · Educational only. Nothing here is investment advice.
Read the next one first.
We read every filing LNSR makes the day it lands, and put it next to what the options market did about it. Members get both, and an alert when a filing arrives.
Cancel anytime · Month to month · Switch tiers whenever